Nutra Pharma Corp. Announces Publication of a Review Article on Cobra Venom and Its Use as an Analgesic

CORAL SPRINGS, FL--(Marketwire - February 01, 2011) -

Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Alternative Therapies in Health and Medicine has published a Review Article on the use of cobra venom as a treatment for pain. The paper, “Cobra Venom: A Review of the Old Alternative to Opiate Analgesics,” was authored by Paul Reid, PhD -- the Chief Executive Officer of Nutra Pharma’s wholly-owned subsidiary, ReceptoPharm.

“We are pleased to see continuing publications on the uses of cobra venom,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “This further emphasizes the need and potential efficacy of venom-based therapeutics like Cobroxin and Nyloxin,” he concluded.

Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.

According to their website, the journal Alternative Therapies in Health and Medicine (ATHM) publishes original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. ATHM was the first journal in the field of complementary and alternative medicine (CAM) to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States, which means that its research articles were cited more frequently than any other journals in the field.

“Most of the published research conducted on the use of cobra venom as an analgesic took place decades ago,” commented Dr. Paul Reid, CEO of ReceptoPharm. “This new review article is meant to educate researchers on the validity of former trials. We can now bring this information up to date by modernizing the data and by conducting new trials with Nutra Pharma’s drugs,” he concluded.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The publication of this review article should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: Pain Relievers Drug Development Biotechnology Pharma